In 2008, twelve-year-old Elana Simon was diagnosed with fibrolamellar hepatocellular carcinoma, a rare and deadly form of liver cancer found in some 200 patients each year. A few years later, after doing research for a high school internship, then sixteen-year-old Simon proposed a study to isolate the genetic mutation responsible for her disease.